CSL inks $1.6B rare disease drug deal with Alentis Therapeutics

CSL has entered into an agreement with Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases, in a deal potentially worth up to $1.6 billion before development funding.